Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

G Curigliano; S Banerjee; A Cervantes; M C Garassino; P Garrido; N Girard; J Haanen; K Jordan; F Lordick; J P Machiels; O Michielin; S Peters; J Tabernero; J Y Douillard; G Pentheroudakis; Panel members

doi:10.1016/j.annonc.2020.07.010

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Ann Oncol. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31.

Authors

G Curigliano¹, S Banerjee², A Cervantes³, M C Garassino⁴, P Garrido⁵, N Girard⁶, J Haanen⁷, K Jordan⁸, F Lordick⁹, J P Machiels¹⁰, O Michielin¹¹, S Peters¹¹, J Tabernero¹², J Y Douillard¹³, G Pentheroudakis¹⁴; Panel members

Collaborators

Panel members:
A Addeo, L Albiges, P A Ascierto, S Banerjee, F Barlesi, C Caldas, F Cardoso, A Cervantes, I F Chaberny, N I Cherny, T K Choueiri, M L K Chua, C Criscitiello, G Curigliano, E de Azambuja, D De Ruysscher, E de Vries, R Dent, J Y Douillard, D D'Ugo, R Dziadziuszko, C Faivre-Finn, E Felip, M Garassino, P Garrido, N Girard, R Glynne-Jones, V Golfinopoulos, J Haanen, E Hamilton, P A Jänne, K Jordan, R Kanesvaran, S B Kim, U G Liebert, F Lordick, J P Machiels, O Michielin, T S K Mok, G Morgan, R Obermannova, K Park, A Passaro, G Pentheroudakis, S Peters, M Reck, R Salazar Soler, F Scotté, S Senan, C Sessa, E Smyth, R Soo, J C Soria, J Spicer, F Strasser, J Tabernero, D S W Tan, D Trapani, E Van Cutsem, H van Halteren, P E van Schil, G Veronesi, J Yang

Affiliations

¹ Department of Oncology and Hemato-Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy. Electronic address: [email protected].
² Gynaecology Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
³ Department of Medical Oncology, Biomedical Research Institute, INCLIVA, University of Valencia, Valencia, Spain; Hematology and Medical Oncology, CIBERONC Instituto de Salud Carlos III, Madrid, Spain.
⁴ Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁵ Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain.
⁶ Thoracic Oncology, Université de Lyon, Université Claude Bernard Lyon, Lyon, France; Thoracic Surgery, Département Oncologie Médicale, Institut Curie, Paris, France.
⁷ Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁸ Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
⁹ Department of Institut Roi Albert II, University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany.
¹⁰ Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), Université Catholique de Louvain, Brussels, Belgium.
¹¹ Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
¹² Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
¹³ Department of Medical Oncology, Centre René Gauducheau, Nantes, France.
¹⁴ Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Epirus, Greece.

Abstract

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty ranging from diagnosis to therapeutic planning and treatment during the COVID-19 pandemic.

Publication types

Practice Guideline

MeSH terms

Betacoronavirus*
COVID-19
Consensus*
Coronavirus Infections* / epidemiology
Coronavirus Infections* / immunology
Coronavirus Infections* / therapy
Disease Management
Europe / epidemiology
Granulocyte Colony-Stimulating Factor / pharmacology
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Medical Oncology* / methods
Medical Oncology* / standards
Neoplasms* / epidemiology
Neoplasms* / immunology
Neoplasms* / therapy
Pandemics / prevention & control
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / immunology
Pneumonia, Viral* / therapy
Real-Time Polymerase Chain Reaction / methods
Real-Time Polymerase Chain Reaction / standards
SARS-CoV-2
Societies, Medical* / standards
T-Lymphocytes, Cytotoxic / drug effects
T-Lymphocytes, Cytotoxic / immunology
Telemedicine / methods
Telemedicine / standards

Substances

Granulocyte Colony-Stimulating Factor